Literature DB >> 12767235

Novel processing of beta-amyloid precursor protein catalyzed by membrane type 1 matrix metalloproteinase releases a fragment lacking the inhibitor domain against gelatinase A.

Shouichi Higashi1, Kaoru Miyazaki.   

Abstract

In various mammalian cell lines, beta-amyloid precursor protein (APP) is proteolytically processed to release its NH(2)-terminal extracellular domain as a soluble APP (sAPP) that contains the inhibitor domain against gelatinase A. To investigate roles of sAPP in the regulation of gelatinase A activity, we examined the correlation between the activation of progelatinase A and processing of APP. We found that stimulation of HT1080 fibrosarcoma cells with concanavalin A led to an activation of endogenous progelatinase A and to a novel processing of APP, which releases a COOH-terminally truncated form of sAPP (sAPPtrc) into the culture medium. Reverse zymographic analysis showed that sAPPtrc lacked an inhibitory activity against gelatinase A. Analyses of production of sAPPtrc in the presence of various metalloproteinase inhibitors showed that membrane type 1 matrix metalloproteinase (MT1-MMP), an activator of progelatinase A, is most likely responsible for the production of sAPPtrc. When the concanavalin A-stimulated HT1080 cells were cultured in the condition that inhibited MT1-MMP activity, sAPP and APP were associated with the extracellular matrix deposited by the cells, whereas these gelatinase A inhibitors in the matrix were displaced by sAPPtrc after exertion of MT1-MMP activity. Taken together, these data support a model in which MT1-MMP-catalyzed release of sAPPtrc leads to reduction of the extracellular matrix-associated gelatinase A inhibitor, sAPP, thus making it feasible for gelatinase A to exert proteolytic activity only near its activator, MT1-MMP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767235     DOI: 10.1021/bi020643m

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  16 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Progress in matrix metalloproteinase research.

Authors:  Gillian Murphy; Hideaki Nagase
Journal:  Mol Aspects Med       Date:  2008-05-24

Review 3.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

Review 4.  Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders.

Authors:  Santiago Rivera; Laura García-González; Michel Khrestchatisky; Kévin Baranger
Journal:  Cell Mol Life Sci       Date:  2019-06-13       Impact factor: 9.261

Review 5.  Revisiting APP secretases: an overview on the holistic effects of retinoic acid receptor stimulation in APP processing.

Authors:  José J M Vitória; Diogo Trigo; Odete A B da Cruz E Silva
Journal:  Cell Mol Life Sci       Date:  2022-01-28       Impact factor: 9.261

Review 6.  Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy.

Authors:  Alex Y Strongin
Journal:  Biochim Biophys Acta       Date:  2009-05-04

7.  Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding.

Authors:  Georgina S Butler; Richard A Dean; Eric M Tam; Christopher M Overall
Journal:  Mol Cell Biol       Date:  2008-05-27       Impact factor: 4.272

8.  Few-layer bismuth selenides exfoliated by hemin inhibit amyloid-β1-42 fibril formation.

Authors:  Jian Peng; Yunjing Xiong; Zhiqin Lin; Liping Sun; Jian Weng
Journal:  Sci Rep       Date:  2015-05-28       Impact factor: 4.379

9.  η-Secretase processing of APP inhibits neuronal activity in the hippocampus.

Authors:  Michael Willem; Sabina Tahirovic; Marc Aurel Busche; Saak V Ovsepian; Magda Chafai; Scherazad Kootar; Daniel Hornburg; Lewis D B Evans; Steven Moore; Anna Daria; Heike Hampel; Veronika Müller; Camilla Giudici; Brigitte Nuscher; Andrea Wenninger-Weinzierl; Elisabeth Kremmer; Michael T Heneka; Dietmar R Thal; Vilmantas Giedraitis; Lars Lannfelt; Ulrike Müller; Frederick J Livesey; Felix Meissner; Jochen Herms; Arthur Konnerth; Hélène Marie; Christian Haass
Journal:  Nature       Date:  2015-08-31       Impact factor: 49.962

10.  Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities.

Authors:  Margaret W Ndinguri; Manishabrata Bhowmick; Dorota Tokmina-Roszyk; Trista K Robichaud; Gregg B Fields
Journal:  Molecules       Date:  2012-11-30       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.